Combinación de láser y ranibizumab en el manejo del tumor retiniano vasoproliferativo

Purpose: To describe patients with intermediate uveitis complicated by vasoproliferative tumors (VPTs). Methods: Data were collected at seven Uveitis/Ocular Oncology centers on demographic, ophthalmic findings at baseline and at follow-up, and on imaging. The therapeutic intervention, final visual acuity, and duration of follow-up were recorded. Results: A total of 36 eyes from 34 patients (12 men, 22 women; mean age 35.3 ± 14.2 years) were included in this study. Visual acuity at presentation ranged from 20/40 to counting fingers. At the time of VPT diagnosis, intermediate uveitis was active in all eyes. The mean VPT thickness was 3.06 ± 0.86 mm. Local treatment to the VPT was provide in 22 eyes (61.1%) and no local treatment to the VPT in 14 eyes (38.9%). After the VPT was detected, systemic or local treatment for the inflammation was initiated and on follow-up FAs 94.4% of the eyes showed resolution of the vascular leakage. During follow-up of 35.8 months, the 22 VPTs treated locally had a reduction in the tumor thickness to 1.25 mm, whereas the 14 VPTs untreated remained stable (final mean tumor thickness 2.65 mm). Conclusion: The presence of active intermediate uveitis accompanied by VPTs suggests the need for an aggressive uveitis treatment.

show abstract

Vasoproliferative Tumors in Intermediate Uveitis

Pichi

Neri

Agarwal

et al. 2020

Retina

View full text Add to dashboard Cite

show abstract

Robotic‐assisted radiosurgery for the treatment of vasoproliferative tumours

Schmelter

Fuerweger

Muacevic³

et al. 2020

Acta Ophthalmologica

View full text Add to dashboard Cite

Purpose Vasoproliferative tumours (VPT) are a rare but benign entity that can lead to severe visual acuity deterioration. There is no standard of care, and depending on the degree of clinical features, including tumour size and dissemination, visual acuity and subretinal fluid, treatment options include observation, cryotherapy and brachytherapy. Particularly in larger tumours, brachytherapy has advantages over other options, although higher radiation doses and the need for surgical application are disadvantages of this otherwise effective treatment option. CyberKnife radiosurgery might represent an alternative therapeutic option as no surgical intervention is needed and radiation doses are lower. Methods All patients diagnosed with vasoproliferative tumors who were treated with CyberKnife radiosurgery with a minimum follow‐up time of 12 months were included in this case series. We recorded visual acuity, number of lesions, central retinal thickness with optical coherence tomography (OCT) and reflectivity using A‐scan standardizes echography every three months. Results A total of four patients with a median age of 34 years (range: 24 – 51) who were observed over an average of 26.5 months (range: 17 – 49 months) matched our inclusion criteria. We appreciated stabilization or increase in visual acuity in all four patients and a regression in tumour thickness with subsequent increase in internal reflectivity as a marker of increasing fibrosis. Conclusion We observed good visual and functional outcome following CyberKnife therapy for VPT. We believe that further studies should be pursued to evaluate CyberKnife therapy for the treatment of VPT not treatable with cryo‐ or lasertherapy.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Combinación de láser y ranibizumab en el manejo del tumor retiniano vasoproliferativo

Cited by 2 publications

References 10 publications

Vasoproliferative Tumors in Intermediate Uveitis

Vasoproliferative Tumors in Intermediate Uveitis

Robotic‐assisted radiosurgery for the treatment of vasoproliferative tumours

Contact Info

Product

Resources

About